ClinicalTrials.gg
CompletedNCT06627088Updated Jan 24, 2025

A Study of LY4100511 (DC-853) Mass Balance and Absolute Bioavailability of LY4100511 in Healthy Male Participants

A Phase 1 interventional study of LY4100511 (DC-853) and [14C]-LY4100511 (DC-853) Administered oral dose in Healthy, sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-24.

Sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company (part of Eli Lilly and Company) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Dec 2024, 1 year 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The study has two parts, Part A and Part B. The purpose of Part A is to determine the absorption, metabolism, and excretion (AME) of [14C]-LY4100511 and to characterize and determine the metabolites present in plasma, urine, and feces in healthy male participants after a single oral dose of LY4100511. The purpose of Part B is to determine the absolute bioavailability of LY4100511 in humans, to further analyze the rate and routes of excretion, including the mass balance, and to further investigate the pharmacokinetics (PK) of [14C]-LY4100511, LY4100511, and TRA.

02

Conditions studied

  • Healthy

Keywords

  • LY4100511
  • DC-853
03

In context

Lead sponsor

DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company is the lead sponsor of 10 studies on the registry; none are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 4 (40%) have results posted.

First submitted after DICE Therapeutics, Inc. became part of Eli Lilly and Company.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • between 18.0 and 32.0 kilogram per square meter (kg/m2), inclusive, and a body weight of ≥50 kilogram (kg)
  • In good health and determined by no finding from medical history, 12-lead and vital signs measurements, and clinical laboratory evaluations (congenital nonhemolytic hyperbilirubinemia, e.g., suspicion of Gilbert's syndrome based on total and direct is not acceptable) at screening and check-in, and from the physical examination at check-in, as assessed by the Investigator or designee
  • History of a minimum of 1 bowel movement per day.
  • Able to provide a fecal sample between check-in on Day-2 and oral dosing on Day 1.

Exclusion criteria

Exclusion Criteria:

  • Have a 12-lead abnormality that, in the opinion of the Investigator

    • increases the risks associated with participating in the study
    • may confound ECG data analysis
    • a \& > 450 msec
    • short PR interval \& \<120 msec or PR interval >220 msec
    • second- or third-degree atrioventricular block
    • intraventricular conduction delay with QRS 120 msec
    • right bundle branch block
    • left bundle branch block, or
    • Wolff Parkinson-White syndrome.
  • Have a current or recent acute, active infection (for example, for at least 30 days before screening and up to check-in, participants must have no symptoms or signs of infection in the absence of any anti-infective treatment).
  • Had any within the past 5 years. Exceptions: successfully treated basal cell skin carcinoma or squamous cell skin carcinoma, with no evidence of recurrence or disease within the 3 years prior to baseline.
  • Are .
  • Have inflammatory bowel disease (IBD)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Part A LY4100511 (tablet formulation) and [14C]-LY4100511 capsule

    Participants will receive a single oral dose 1 or dose 2 unlabeled LY4100511 (tablet formulation) administered with a dose 1 \[14C\]-LY4100511 capsule containing approximately 100 µCi (3.7 MBq) of radioactivity in the fasted state

    Drug: LY4100511 (DC-853) · Drug: [14C]-LY4100511 (DC-853) Administered oral dose

  • Experimental
    Part B LY4100511 (tablet formulation) and [14C]-LY4100511

    Participants will receive a single oral dose 1 or dose 2 unlabeled LY4100511 (tablet formulation) in the fasted state, followed by a single intravenous (IV) dose of of \[14C\]-LY4100511, containing ≤1 μCi (≤37 kBq) of radioactivity, administered as an infusion.

    Drug: LY4100511 (DC-853) · Drug: [14C]-LY4100511 (DC-853)

Interventions

06

What researchers measure

Primary outcomes

  1. Part A: Total Radioactivity Recovery and Excretion (TRA)

    Total radioactivity recovery and excretion (fet1-t2 and Aet1-t2) in urine and feces (and vomitus, if available)

    Time frame: Up until Day 15

  2. Part A: Pharmacokinetic (PK): Area Under the Concentration from Time 0 to Infinity (AUC0-∞) for [14C] LY4100511

    Time frame: Up until Day 15

  3. Part A: Pharmacokinetic (PK): Area Under the Concentration from Time 0 to Infinity (AUC0-∞) for LY4100511

    Time frame: Up until Day 15

  4. Part A: Pharmacokinetic (PK): Area Under the Concentration from Time 0 to Infinity (AUC0-∞) for TRA

    Time frame: Up until Day 15

  5. Part A: PK Area Under Concentration from 0 to Last Measurable Concentration (AUC0-tlast) for [14C] LY4100511

    Time frame: Up until Day 15

  6. Part A: PK Area Under Concentration from 0 to Last Measurable Concentration (AUC0-tlast) for LY4100511

    Time frame: Up until Day 15

  7. Part A: PK Area Under Concentration from 0 to Last Measurable Concentration (AUC0-tlast) for TRA

    Time frame: Up until Day 15

  8. Part A: PK Maximum Observed Plasma Concentration (Cmax) for [14C] LY4100511

    Time frame: Up until Day 15

  9. Part A: PK Maximum Observed Plasma Concentration (Cmax) for LY4100511

    Time frame: Up until Day 15

  10. Part A: PK Maximum Observed Plasma Concentration (Cmax) for TRA

    Time frame: Up until Day 15

  11. Part A: PK Time to Maximum Observed Plasma Concentration (tmax) for [14C] LY4100511

    Time frame: Up until Day 15

  12. Part A: PK Time to Maximum Observed Plasma Concentration (tmax) for LY4100511

    Time frame: Up until Day 15

  13. Part A: PK Time to Maximum Observed Plasma Concentration (tmax) for TRA

    Time frame: Up until Day 15

  14. Part A: PK Terminal Elimination Half Life (t1/2) for [14C] LY4100511

    Time frame: Up until Day 15

  15. Part A: PK Terminal Elimination Half Life (t1/2) for LY4100511

    Time frame: Up until Day 15

  16. Part A: PK Terminal Elimination Half Life (t1/2) for TRA

    Time frame: Up until Day 15

  17. Part A: Urinary Recovery and Excretion of TRA (Aet1-t2)

    Time frame: Up until Day 15

  18. Part A: Urinary Recovery and Excretion of [14C] LY4100511 (Aet1-t2)

    Time frame: Up until Day 15

  19. Part A: Renal clearance of [14C] LY4100511 (CLR)

    Time frame: Up until Day 15

  20. Part B: Pharmacokinetic (PK): absolute bioavailability (Fabs) of LY4100511

    Time frame: Up until Day 6

  21. Part B: Recovery of TRA in urine and feces

    Time frame: Up until Day 6

  22. Part B: Recovery of [14C]-LY4100511 in feces (Aet1-t2) following IV dosing

    Time frame: Up until Day 6

  23. Part B: Recovery of [14C]-LY4100511 in urine (Aet1-t2) following IV dosing

    Time frame: Up until Day 6

  24. Part B: PK Area Under Concentration from 0 to Last Measurable Concentration (AUC0-tlast) of LY4100511 following IV dosing

    Time frame: Up until Day 6

  25. Part B: PK Maximum Observed Plasma Concentration (Cmax) of LY4100511following IV dosing

    Time frame: Up until Day 6

  26. Part B: PK Time to Maximum Observed Plasma Concentration (tmax) of LY4100511following IV dosing

    Time frame: Up until Day 6

  27. Part B: PK Terminal Elimination Half Life (t1/2) following IV dosing

    Time frame: Up until Day 6

  28. Part B: PK Clearance (CL) following IV dosing

    Time frame: Up until Day 6

  29. Part B: PK renal clearance (CLr) following IV dosing [Time Frame: Up until Day 6]

    Time frame: Up until Day 6

Secondary outcomes

  1. Number of Participants with One or More Adverse Events (AEs), and Serious Adverse Events (SAEs) considered by the investigator to be related to study drug administration

    A summary of AEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events Module.

    Time frame: Up until Day 8

07

Study locations

1 site
  • Fortrea Clinical Research Unit
    Madison, Wisconsin 53704, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2024 to primary completion in Dec 2024, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2024
First posted
Oct 4, 2024
StartActual
Aug 23, 2024
Primary completionActual
Dec 31, 2024
CompletionActual
Dec 31, 2024
Last update
Jan 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06627088
Responsible party
Sponsor
First posted
Oct 4, 2024
Start date
Aug 23, 2024
Primary completion
Dec 31, 2024
Completion
Dec 31, 2024
Last update
Jan 24, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Simepdekinra

Start the discussion